Table 2.

List of antigens targeted by CART in pre-clinical glioma model.

Antigen	Generation	Other Treatments/Modifications	Reference
NKG2D	Second Generation	Radiotherapy/ NKG2D–CD3ζ-DAP10	Weiss et al. (49)
GD2	Third Generation	Engineered with active IL-7 receptor (C7R) and a 41BB.ζ signaling endodomain	Shum et al. (50)
IL13Rα2	Second Generation	Engineered contain either a CD28.ζ, 41BB.ζ CD28.OX40.ζ, or CD28.41BB.ζ endodomain	Krenciute et al. (51)
EGFRvIII	Third Generation	Engineered to express miR-17-92 with CD28, 41BB and CD3ζ signaling	Ohno et al. (52)
EGFRvIII	Third Generation	Engineered to contain a CD28-41BB-CD3ζ endodomain	Choi et al. (53)
EGFRvIII	Second Generation	Engineered with ICOS and CD3ζ signaling domain	Shen et al. (54)
NY-ESO-1	N/A	Decitabine, in culture/ modified CDR	Everson et al. (55)
EGFRvIII	Third Generation	Engineered with mouse CD8 trans-membrane and mouse CD28, 4-1BB, and CD3ζ intracellular regions	Sampson et al. (56)